



Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

Date: 09th June, 2026

To,
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Scrip Code: 544759, Scrip ID: GLPL,

Subject: Outcome of Board Meeting held today, i.e., 09th June, 2026.

Dear Sir/Madam,

We wish to inform you that in compliance with the provisions of Regulation 33 read with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the Board of Directors at their meeting held today, i.e. have inter alia approved the following:

1. The Standalone Audited Financial Results set out in compliance with applicable Accounting Standards for the half-year and year ended 31st March, 2026 together with Statement of Assets and Liabilities.
2. Appointment of **M/s. Kunal Dutt & Associates, Practicing Company Secretaries, Membership No.: FCS 8831** as Internal Auditor of the Company, from the financial year 2026-27 & onwards. The details required under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023 are mentioned below as **Annexure-I**.



Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

The Board Meeting commenced at 04:30 P.M. and concluded at 05:06 P.M.

The aforesaid results are also being disseminated on company's website at www.goldlinepharma.in.

You are requested to kindly take the information on your record.

Yours faithfully,

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi

Company Secretary cum Compliance Officer



Adds life to health

Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

Annexure A

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular.

| Particulars | Details |
|---|---|
| Name of Internal Auditor | M/s. Kunal Dutt & Associates |
| Date of Appointment | 09/06/2026 |
| Brief Profile | M/s. Kunal Dutt & Associates is a Practicing Company Secretaries firm offering specialized services in corporate law advisory, secretarial audits, compliance management, corporate governance, audit and assurance, tax and regulatory matters, transaction advisory, and consulting. The firm is committed to delivering practical, value-driven, and compliance-oriented solutions while keeping in view the regulatory and commercial environment within which its clients operate. |
| Disclosure of relationships between directors | Not related to any Director/KMP of the Company. |

**Independent Auditor's Report on half yearly and year to Date Audited
Financial Results of the Company pursuant to Regulation 33 of SEBI.
(Listing Obligations and Disclosure Requirements) Regulations, 2015 as
amended.**

To
The Board of Directors,
Goldline Pharmaceutical Limited

Report on the Audit of Financial Statements

Opinion

We have audited the accompanying Financial Results of Goldline Pharmaceutical Limited ("the Company") for the Half Year ended 31st March 2026 and the year to date results from 1st April 2025 to 31st March 2026, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ("the Regulation") as amended (the "Listing Regulations") applicable to SME Listed entities. This statement is the responsibility of the Company's Management and has been approved reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on 09th June 2026. Our Responsibility is to issue an audit report on these financial statements based on our audit.

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the Net Profit/Loss and Other Financial Information of the Company for the half year ended March 31st, 2026 and year to date results for the period from 1st April 2025 to March 31st, 2026.



Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter (EOM)

We draw attention that the Company was listed on 19th of May 2026, on Bombay Stock Exchange's SME Platform subsequent to the reporting period. Our opinion is not modified in respect of this matter.

Other Matters

The Financial Results dealt with by this report have been prepared for the express purpose of filing with Stock Exchanges. These results are based on and should be read with the Audited Financial Statements of the Company for the year ended 31st March 2026 on which we issued an unmodified audit opinion.

Our opinion is not modified in respect of above matters.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



- f) Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Final Results. We are responsible for the direction, supervision and performance of the audit of financial information of which we are the independent auditor.

Materiality is the magnitude of misstatements in the Financial Results that individually or in aggregate makes it probable that the economic decision of reasonably knowledgeable user of the Financial Result may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect on any identified misstatements in the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For B Shroff & Co.

Chartered Accountants
Firm Reg. No. 006514W



CA Nilesh Tiwari

Partner

Membership No. 130513

UDIN : 26130513PWSFZF3742



Place: Nagpur

Date: 9th June 2026



Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2026


(Rs. In Lacs)

| Particulars | Note | Half Year Ended | | Year Ended | |
|--|-----------|-----------------|-----------------|-----------------|-----------------|
| | | Audited | Audited | Audited | Audited |
| | | 31th March 2026 | 31th Sept 2025 | 31st March 2026 | 31st March 2025 |
| I. Revenue | | | | | |
| Revenue from operations | 21 | 1,730.55 | 1,389.21 | 3,119.76 | 2,805.57 |
| II. Other income | 22 | 0.11 | - | 0.11 | - |
| III. Total Income (I +II) | | 1,730.67 | 1,389.21 | 3,119.88 | 2,805.57 |
| IV. Expenses | | | | | |
| Cost of materials consumed | | | - | | - |
| Purchases & Direct Expenses | 23 | 476.39 | 586.13 | 1,062.52 | 1,008.80 |
| Changes in Inventories of Finished Goods | 24 | 111.31 | (54.81) | 56.50 | 71.34 |
| Work-in-Progress and Stock-in-Trade | | - | - | - | - |
| Employee benefits expense | 25 | 373.89 | 333.12 | 707.01 | 575.40 |
| Finance costs | 26 | 64.83 | 66.63 | 131.46 | 172.34 |
| Depreciation & amortisation Expense | | 12.32 | 11.81 | 24.13 | 25.03 |
| Other Expenses | 27 | 338.48 | 261.24 | 599.72 | 566.82 |
| Total expenses | | 1,377.22 | 1,204.12 | 2,581.34 | 2,419.73 |
| V. Profit before exceptional and extraordinary items and tax (III-IV) | | 353.45 | 185.09 | 538.54 | 385.84 |
| VI. Exceptional items | | | | | - |
| VII. Profit before extraordinary items and tax (V - VI) | | 353.45 | 185.09 | 538.54 | 385.84 |
| VIII. Extraordinary items | | | | | - |
| IX. Profit before tax (VII-VIII) | | 353.45 | 185.09 | 538.54 | 385.84 |
| X. Income for earlier Year | | | | | - |
| XI. Tax expense: | | | | | |
| (1) Current tax | | 97.10 | 46.33 | 143.43 | 99.14 |
| (2) Deferred tax Asset / (Liability) | | 19.80 | (3.20) | 16.60 | (3.27) |
| (3) Income tax for earlier year | | | - | | - |
| XII Profit After Tax from continuing operations | | 276.15 | 135.56 | 411.71 | 283.43 |
| XIII Earning per equity Share : | | | | | |
| (1) Basic & Diluted | 29 | 4.00 | 1.96 | 5.97 | 4.11 |
| Summary of Significant Accounting Policies | 1 | | | | |

The accompanying notes are an integral part of the financial statements.

Registered & Corporate Office.: 103, F1, Leela Apartment, Near Shanidham, Shilpa Society, Saptagiri Nagar, Nagpur - 440015, Maharashtra, India
 Website.: www.goldlinepharma.in, Ph.: 0712-2786666, Mobile.: +91- 9561132666 , Email.: info@goldlinepharma.in, goldlinepharmaceuticalsld@gmail.com

For Goldline Pharmaceutical Limited


Amol Laxmikant Mujumdar
 Managing Director
 DIN: 01910549
 Date: 09/06/2026
 Place: Nagpur





Goldline Pharmaceutical Limited

CIN: U51397MH2004PLC147806


BALANCE SHEET AS AT 31ST MARCH 2026

(Rs. In Lacs)

| | Particulars | Note | As At March 31, 2026 | As At March 31, 2025 |
|--|---|-----------|----------------------|----------------------|
| | EQUITY AND LIABILITIES | | | |
| 1 | Shareholder's funds | | | |
| | (a) Share Capital | 2 | 870.70 | 870.70 |
| | (b) Reserves and surplus | 3 | 554.26 | 155.33 |
| | | | 1,424.96 | 1,026.03 |
| 2 | Share Application Money Pending Allotment | | - | - |
| 3 | Non-current liabilities | | | |
| | (a) Long-term borrowings | 4 | 146.32 | 319.27 |
| | (b) Deferred Tax Liabilities (Net) | 5 | - | 8.92 |
| | (c) Other Long Term Liabilities | 6 | 22.00 | 22.00 |
| | (d) Long-term provisions | 7 | 82.45 | 65.97 |
| | | | 250.77 | 416.16 |
| 4 | Current liabilities | | | |
| | (a) Short-term borrowings | 8 | 769.85 | 784.17 |
| | (b) Trade payables | 9 | | |
| | (i) Total outstanding dues of micro enterprises and small enterprises | | 93.71 | 135.23 |
| | (ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | | 91.36 | 70.50 |
| | (c) Other current liabilities | 10 | 112.37 | 83.11 |
| | (d) Short-term provisions | 11 | 144.08 | 103.49 |
| | | | 1,211.36 | 1,176.51 |
| | TOTAL | | 2,887.09 | 2,618.70 |
| | ASSETS | | | |
| 1 | Non-current assets | | | |
| | (a) Property, Plant And Equipment & Intangible Assets | 12 | | |
| | (i) Property, Plant And Equipment | | 264.91 | 283.67 |
| | (ii) Intangible Assets | | 5.60 | 5.30 |
| | (iii) Capital WIP | | - | - |
| | (iv) Tangible assets under development | | - | - |
| | (b) Non-current investments | 13 | 2.50 | 2.50 |
| | (c) Defered Tax Asset (net) | 14 | 7.68 | - |
| | (d) Long-term loans and advances | 15 | 1.56 | 1.56 |
| | (e) Other Non Current Assets | | - | - |
| | TOTAL (1) | | 282.25 | 293.03 |
| 2 | Current assets | | | |
| | (a) Current investments | | - | - |
| | (b) Inventories | 16 | 621.22 | 677.72 |
| | (c) Trade receivables | 17 | 1,612.81 | 1,069.32 |
| | (d) Cash and cash equivalents | 18 | 59.24 | 123.97 |
| | (e) Short-term loans and advances | 19 | 198.35 | 287.46 |
| | (f) Other Current Assets | 20 | 113.22 | 167.19 |
| | TOTAL (2) | | 2,604.83 | 2,325.66 |
| | TOTAL (1+2) | | 2,887.09 | 2,618.70 |
| | Summary of Significant Accounting Policies | 1 | | |
| The accompanying notes are an integral part of the financial statements. | | | | |

Registered & Corporate Office.: 103, F1, Leela Apartment, Near Shanidham, Shilpa Society, Saptagiri Nagar, Nagpur - 440015, Maharashtra, India
 Website.: www.goldlinepharma.in, Ph.: 0712-2786666, Mobile.: +91- 9561132666 , Email.: info@goldlinepharma.in, goldlinepharmaceuticalsld@gmail.com

For Goldline Pharmaceutical Limited


 Amol Laxmikanth Mujumdar
 Managing Director
 DIN: 01910549
 Date: 09/06/2026
 Place: Nagpur





Goldline Pharmaceutical Limited

CIN: U51397MH2004PLC147806

Statement of Cash Flow for the Year Ended 31st March, 2026

(Rs. In Lacs)

| Particulars | March 31st , 2026 | March 31st , 2025 |
|---|-------------------|-------------------|
| Cash Flow from Operating Activities | | |
| Profit/(Loss) Before Extraordinary Losses & Tax | 538.54 | 385.84 |
| Adjustment for | | |
| Depreciation | 24.13 | 25.03 |
| Finance Cost | 131.46 | 172.34 |
| Non Operating Income | 0.11 | - |
| Loss From Sale of Fixed Assets | - | 9.12 |
| Prior Period Adjustments | - | 0.06 |
| Operating cash flow before working capital changes | 694.24 | 592.39 |
| Decrease(Increase) in Other Current Assets | | |
| Inventories | 56.50 | 71.34 |
| Trade Receivables | (543.48) | (172.66) |
| Short Term Loans & Advances | 89.11 | (112.02) |
| Other Current Assets | 57.27 | (42.36) |
| (Decrease)Increase in Current Liabilities/Non Current Liability | | |
| Trade Payables | (20.67) | 63.82 |
| Other Current Liabilities | 29.25 | (4.82) |
| Short term Provisions | 0.91 | 5.16 |
| Other Long term Liability | - | - |
| Other Long term Provisions | 16.48 | 8.56 |
| Working Capital Change | (314.64) | (182.99) |
| Cash flow from Extraordinary items | - | - |
| Cash generated from operations | 379.60 | 409.40 |
| Income Tax Paid | 98.14 | 91.28 |
| Cash Flow from Operating activities (A) | 281.46 | 318.12 |
| Non-Operating Income | (0.11) | - |
| Purchase of Fixed Assets | (5.67) | (20.71) |
| Decrease in Depreciation Reserve | - | - |
| Sale/(Purchase) of Property Plant & Equipment | - | 37.84 |
| Increase/(Decrease) in Long Term Loan & Advances | - | - |
| Increase in Non Current Investment/Assets | - | (0.90) |
| Net Cash from Investing activities (B) | (5.78) | 16.23 |
| Cash Flow from Financing activities:- | | |
| Proceeds from Share Application Money | - | - |
| Proceeds from Share Capital | - | - |
| Proceeds/(Repayment) from/to Long term borrowings (Net) | (172.95) | (307.17) |
| Proceeds/(Repayment) from/to Short term borrowings (Net) | (14.32) | 211.55 |
| Proceeds from security Premium | - | - |
| Finance Cost | (131.46) | (172.34) |
| Dividend paid During the year | (21.68) | (21.47) |
| Net Cash Flow from Financing activities (C) | (340.41) | (289.42) |
| Net Increase in Cash & Cash Equivalents(A+B+C) | (64.73) | 44.92 |
| Cash & Cash Equivalents (Refer Note 20) | | |
| - At the beginning of the year | 123.97 | 79.05 |
| - At the end of the year | 59.24 | 123.97 |

Registered & Corporate Office.: 103, F1, Leela Apartment, Near Shanidham, Shilpa Society, Saptagiri Nagar, Nagpur - 440015, Maharashtra, India
Website.: www.goldlinepharma.in, Ph.: 0712-2786666, Mobile.: +91- 9561132666 , Email.: info@goldlinepharma.in, goldlinepharmaceuticalsLtd@gmail.com

For Goldline Pharmaceutical Limited

Amol Laxmikant Mujumdar
Managing Director
DIN: 01910549
Date: 09/06/2026
Place: Nagpur





Adds life to health

Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

Notes to the Financial Results of Goldline Pharmaceutical Limited

For the year ended 31st March 2026

1. The above said financial results have been reviewed by the Audit committee in their meeting on 09-06-2026 and approved by board of Directors in their meeting held on 09-06-2026.
2. The company is engaged in only one business of Wholesale Trade of Pharmaceuticals hence no information has been furnished in accordance with AS 17 on "Segment Reporting" issued by the Institute of Chartered Accountants of India.
3. There are no investor complaints received/pending as on 31.03.2026.
4. Figures of previous period/ year have been regrouped/ recast wherever necessary, in order to make them comparable.
5. As per MCA notification dated 16th February, 2015, companies whose shares are listed on SME as referred in Chapter XB(LODR)2015 are exempted from adoption of IND AS. As company is covered under exempted category, it has not adopted IND AS for the preparation of financial results.
6. Figures of last Half year are the balancing figures between audited figures in respect of the full financial year.
7. The Company was listed on 19th of May 2026, on Bombay Stock Exchange's SME Platform subsequent to the reporting period.
8. The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. <https://www.goldlinepharma.in>.

For Goldline Pharmaceutical Limited

Amol Laxmikant Mujumdar

Managing Director

DIN: 01910549

Date: 09/06/2026

Place: Nagpur





Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

Date: 09th June, 2026

To,
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Scrip Code: 544759, Scrip ID: GLPL

Subject: - Declaration on Auditor's Report under Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir/Madam,

Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 we hereby declare and confirm that the Auditor's Report on Standalone Financial Statements and results for the Half-Year and Year ended 31st March, 2026 which are being sent herewith are unmodified and without any qualification.

Thanking you,

Yours faithfully,

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi

Company Secretary cum Compliance Officer